FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891129265> ?p ?o ?g. }

• W2891129265 endingPage "205" @default.
• W2891129265 startingPage "195" @default.
• W2891129265 abstract "The oral administration of celecoxib (CLX) is a real problem because of its low aqueous solubility that results in high variability in absorption and its severe adverse effect such as cardiotoxic effects and gastrointestinal toxicity. Self-nanoemulsifying drug delivery systems (SNEDDS) can enhance the poor dissolution and erratic absorption of poorly water-soluble drugs such as CLX. This study was conducted to investigate the potential of SNEDDS to enhance the efficacy of CLX on inflamed mucous tissue and reduce systemic adverse effects by increasing its poor dissolution properties. A pseudo-ternary phase diagram was derived from the results of CLX solubility experiments in various excipients. These studies revealed the use of Labrafil M 2515 CS as oil, tween 80 as a surfactant, and polyethylene glycol 400 as a co-surfactant for the optimization of SNEDDS formulations. Eight formulations were formulated and characterized by their particle size, polydispersity index, viscosity, globular shape, drug solubility, self-emulsification efficiency, in vitro drug release, and permeation. The anti-inflammatory effect of CLX-SNEDDS was evaluated by carrageenan-induced cheek oedema in rats. The cheeks were treated with CLX-SNEDDS before oedema induction and then noticed for narrow periods (2 h) followed by histopathological studies to determine the efficacy of treatment. The selected formulations (F3 and F5) showed spherical morphologies under transmission electron microscopy, mean droplet sizes of 116.9 ± 1.78 and 124 ± 1.87 nm, respectively, complete in vitro drug release, and high cumulative amounts of drug permeation in 8 h. They also showed significant remarkable cheek oedema inhibition in comparison with the control groups (p < 0.05). CLX-SNEDDS was found to achieve effective local therapeutic concentration and intended to reduce cheek oedema, congestive capillary, inflammatory cells, and side effects due to lower dose size." @default.
• W2891129265 created "2018-09-27" @default.
• W2891129265 creator A5009549972 @default.
• W2891129265 creator A5028331711 @default.
• W2891129265 creator A5049521775 @default.
• W2891129265 creator A5081493876 @default.
• W2891129265 date "2018-11-23" @default.
• W2891129265 modified "2023-10-03" @default.
• W2891129265 title "Formulation development of self-nanoemulsifying drug delivery system of celecoxib for the management of oral cavity inflammation" @default.
• W2891129265 cites W1657403456 @default.
• W2891129265 cites W1947852204 @default.
• W2891129265 cites W1965448101 @default.
• W2891129265 cites W1973656357 @default.
• W2891129265 cites W1974008347 @default.
• W2891129265 cites W1974112784 @default.
• W2891129265 cites W1980000756 @default.
• W2891129265 cites W1989426152 @default.
• W2891129265 cites W1996415204 @default.
• W2891129265 cites W1997384329 @default.
• W2891129265 cites W2001533174 @default.
• W2891129265 cites W2003952694 @default.
• W2891129265 cites W2005544744 @default.
• W2891129265 cites W2015278293 @default.
• W2891129265 cites W2018081140 @default.
• W2891129265 cites W2020487511 @default.
• W2891129265 cites W2038322578 @default.
• W2891129265 cites W2039748268 @default.
• W2891129265 cites W2041698088 @default.
• W2891129265 cites W2043625659 @default.
• W2891129265 cites W2045588696 @default.
• W2891129265 cites W2045800643 @default.
• W2891129265 cites W2049730459 @default.
• W2891129265 cites W2075379117 @default.
• W2891129265 cites W2087335987 @default.
• W2891129265 cites W2090241136 @default.
• W2891129265 cites W2090485171 @default.
• W2891129265 cites W2094332572 @default.
• W2891129265 cites W2100766193 @default.
• W2891129265 cites W2126434063 @default.
• W2891129265 cites W2137457370 @default.
• W2891129265 cites W2296315220 @default.
• W2891129265 cites W2302081134 @default.
• W2891129265 cites W2322117179 @default.
• W2891129265 cites W2470885417 @default.
• W2891129265 cites W2534618506 @default.
• W2891129265 cites W2589011850 @default.
• W2891129265 cites W4242516997 @default.
• W2891129265 cites W561173819 @default.
• W2891129265 doi "https://doi.org/10.1080/08982104.2018.1524484" @default.
• W2891129265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30221598" @default.
• W2891129265 hasPublicationYear "2018" @default.
• W2891129265 type Work @default.
• W2891129265 sameAs 2891129265 @default.
• W2891129265 citedByCount "8" @default.
• W2891129265 countsByYear W28911292652019 @default.
• W2891129265 countsByYear W28911292652021 @default.
• W2891129265 countsByYear W28911292652022 @default.
• W2891129265 countsByYear W28911292652023 @default.
• W2891129265 crossrefType "journal-article" @default.
• W2891129265 hasAuthorship W2891129265A5009549972 @default.
• W2891129265 hasAuthorship W2891129265A5028331711 @default.
• W2891129265 hasAuthorship W2891129265A5049521775 @default.
• W2891129265 hasAuthorship W2891129265A5081493876 @default.
• W2891129265 hasConcept C125287762 @default.
• W2891129265 hasConcept C155574463 @default.
• W2891129265 hasConcept C159985019 @default.
• W2891129265 hasConcept C178790620 @default.
• W2891129265 hasConcept C181389837 @default.
• W2891129265 hasConcept C185592680 @default.
• W2891129265 hasConcept C192562407 @default.
• W2891129265 hasConcept C2777056448 @default.
• W2891129265 hasConcept C2779820397 @default.
• W2891129265 hasConcept C2780035454 @default.
• W2891129265 hasConcept C41625074 @default.
• W2891129265 hasConcept C43617362 @default.
• W2891129265 hasConcept C50670333 @default.
• W2891129265 hasConcept C55493867 @default.
• W2891129265 hasConcept C58226133 @default.
• W2891129265 hasConcept C71924100 @default.
• W2891129265 hasConcept C98274493 @default.
• W2891129265 hasConceptScore W2891129265C125287762 @default.
• W2891129265 hasConceptScore W2891129265C155574463 @default.
• W2891129265 hasConceptScore W2891129265C159985019 @default.
• W2891129265 hasConceptScore W2891129265C178790620 @default.
• W2891129265 hasConceptScore W2891129265C181389837 @default.
• W2891129265 hasConceptScore W2891129265C185592680 @default.
• W2891129265 hasConceptScore W2891129265C192562407 @default.
• W2891129265 hasConceptScore W2891129265C2777056448 @default.
• W2891129265 hasConceptScore W2891129265C2779820397 @default.
• W2891129265 hasConceptScore W2891129265C2780035454 @default.
• W2891129265 hasConceptScore W2891129265C41625074 @default.
• W2891129265 hasConceptScore W2891129265C43617362 @default.
• W2891129265 hasConceptScore W2891129265C50670333 @default.
• W2891129265 hasConceptScore W2891129265C55493867 @default.
• W2891129265 hasConceptScore W2891129265C58226133 @default.
• W2891129265 hasConceptScore W2891129265C71924100 @default.
• W2891129265 hasConceptScore W2891129265C98274493 @default.
• W2891129265 hasIssue "2" @default.

• next